These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 9100553

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G.
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B, Kann PH.
    Med Klin (Munich); 2004 Oct 15; 99(10):569-77. PubMed ID: 15490072
    [Abstract] [Full Text] [Related]

  • 7. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 15; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 8. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency.
    Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM.
    Clin Endocrinol (Oxf); 1995 Jun 15; 42(6):627-33. PubMed ID: 7634504
    [Abstract] [Full Text] [Related]

  • 9. Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.
    Sartorio A, Ortolani S, Galbiati E, Conte G, Vangeli V, Arosio M, Porretti S, Faglia G.
    J Endocrinol Invest; 2001 Apr 15; 24(4):224-30. PubMed ID: 11383908
    [Abstract] [Full Text] [Related]

  • 10. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
    Lanes R, Gunczler P, Esaa S, Weisinger JR.
    Clin Endocrinol (Oxf); 2002 Dec 15; 57(6):725-30. PubMed ID: 12460321
    [Abstract] [Full Text] [Related]

  • 11. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
    Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U.
    Eur J Endocrinol; 2002 Feb 15; 146(2):187-95. PubMed ID: 11834427
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May 15; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential effects of growth hormone therapy in malnourished hemodialysis patients.
    Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuzer S, Geyer G, Frisch H, Hörl WH, Mayer G, Luger A.
    Kidney Int; 2001 Oct 15; 60(4):1578-85. PubMed ID: 11576376
    [Abstract] [Full Text] [Related]

  • 16. Elderly patients with adult-onset growth hormone deficiency are not osteopenic.
    Toogood AA, Adams JE, O'Neill PA, Shalet SM.
    J Clin Endocrinol Metab; 1997 May 15; 82(5):1462-6. PubMed ID: 9141534
    [Abstract] [Full Text] [Related]

  • 17. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ, Hamdy NA, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 1998 Jun 15; 83(6):2143-8. PubMed ID: 9626153
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 15; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study.
    Sääf M, Hilding A, Thorën M, Troell S, Hall K.
    Eur J Endocrinol; 1999 May 15; 140(5):390-9. PubMed ID: 10229902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.